Cue Biopharma Operating Expenses Growth & History (CUE)
Cue Biopharma's operating expenses was $54.0M for fiscal 2025.
View full Cue Biopharma company overviewCue Biopharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $54.0M | $3.2M | +6.36% |
| 2024 | 2024-12-31 | $50.8M | −$6.9M | −11.89% |
| 2023 | 2023-12-31 | $57.6M | $3.2M | +5.82% |
| 2022 | 2022-12-31 | $54.5M | −$4.2M | −7.13% |
| 2021 | 2021-12-31 | $58.7M | $10.5M | +21.70% |
| 2020 | 2020-12-31 | $48.2M | $8.0M | +19.81% |
| 2019 | 2019-12-31 | $40.2M | $388,316 | +0.97% |
| 2018 | 2018-12-31 | $39.8M | $16.6M | +71.47% |
| 2017 | 2017-12-31 | $23.2M | — | — |
Cue Biopharma quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $95.6M | $84.0M | +724.68% |
| Q1 2026 | 2026-03-31 | $11.0M | −$1.7M | −13.22% |
| Q4 2025 | 2025-12-31 | $20.0M | $8.8M | +78.10% |
| Q3 2025 | 2025-09-30 | $9.7M | −$2.4M | −19.81% |
| Q2 2025 | 2025-06-30 | $11.6M | −$1.5M | −11.13% |
| Q1 2025 | 2025-03-31 | $12.7M | −$1.7M | −11.57% |
| Q4 2024 | 2024-12-31 | $11.2M | −$4.4M | −28.39% |
| Q3 2024 | 2024-09-30 | $12.2M | −$1.4M | −10.12% |
| Q2 2024 | 2024-06-30 | $13.0M | −$1.9M | −12.47% |
| Q1 2024 | 2024-03-31 | $14.4M | $818,000 | +6.03% |
| Q4 2023 | 2023-12-31 | $15.7M | $637,000 | +4.24% |
| Q3 2023 | 2023-09-30 | $13.5M | $2.4M | +21.80% |
| Q2 2023 | 2023-06-30 | $14.9M | $1.8M | +13.59% |
| Q1 2023 | 2023-03-31 | $13.6M | −$1.7M | −10.97% |
| Q4 2022 | 2022-12-31 | $15.0M | −$1.1M | −6.89% |
| Q3 2022 | 2022-09-30 | $11.1M | −$4.3M | −27.99% |
| Q2 2022 | 2022-06-30 | $13.1M | $74,000 | +0.57% |
| Q1 2022 | 2022-03-31 | $15.2M | $1.2M | +8.29% |
| Q4 2021 | 2021-12-31 | $16.1M | $4.7M | +40.85% |
| Q3 2021 | 2021-09-30 | $15.4M | $4.6M | +42.25% |
| Q2 2021 | 2021-06-30 | $13.0M | $1.0M | +8.53% |
| Q1 2021 | 2021-03-31 | $14.1M | $176,000 | +1.27% |
| Q4 2020 | 2020-12-31 | $11.4M | $1.4M | +13.74% |
| Q3 2020 | 2020-09-30 | $10.8M | $2.8M | +34.13% |
| Q2 2020 | 2020-06-30 | $12.0M | $1.7M | +16.83% |
| Q1 2020 | 2020-03-31 | $13.9M | $2.1M | +17.78% |
| Q4 2019 | 2019-12-31 | $10.1M | −$1.4M | −12.20% |
| Q3 2019 | 2019-09-30 | $8.1M | −$5.1M | −38.84% |
| Q2 2019 | 2019-06-30 | $10.3M | $2.6M | +34.56% |
| Q1 2019 | 2019-03-31 | $11.8M | $4.3M | +56.83% |
| Q4 2018 | 2018-12-31 | $11.5M | $1.0M | +9.83% |
| Q3 2018 | 2018-09-30 | $13.2M | $8.2M | +162.48% |
| Q2 2018 | 2018-06-30 | $7.6M | $3.2M | +73.22% |
| Q1 2018 | 2018-03-31 | $7.5M | $4.2M | +124.54% |
| Q4 2017 | 2017-12-31 | $10.4M | — | — |
| Q3 2017 | 2017-09-30 | $5.0M | — | — |
| Q2 2017 | 2017-06-30 | $4.4M | — | — |
| Q1 2017 | 2017-03-31 | $3.4M | — | — |
Cue Biopharma operating expenses trends
Over the last five fiscal years, Cue Biopharma's operating expenses increased from $48.2M to $54.0M, a change of $5.8M. The latest reported quarter, Q2 2026, shows $95.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cue Biopharma source filings ↗